Gene Therapy

According to one study, when genetic testing is coupled with advanced imaging, the chances of identifying keratoconus early are greater.

A synopsis of the findings presented at EURETINA 2022 for ophthalmologists and retina specialists.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

Recent reports of retinal atrophy have raised concerns on potential long-term safety.

The findings of this study may have revealed the crucial role of gene fragments in retinal development and vision.

A novel computational platform identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

According to the Nanoscope Therapeutics, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

Metformin may provide AMD protection; DAVIO presents positive 12-month results; TOWER study reveals new imaging index for AMD.

Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.

Increasing understanding of the genetics behind Usher syndrome suggests that treatment may become possible in the very near future.

Promising gene therapies in development are pinpointing steps in the pathogenic cascades involved in ocular diseases, such as VEGF for wet AMD and CFI for dry AMD.

Options under investigation for the treatment of AMD include interruption of the dry AMD disease process and gene therapy to prompt the retina to heal itself.

An end-of-week review of what happened in ophthalmology from April 9-April 15.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

Sub-retinal injection of adeno-associated virus leads to visual acuity gains.

A team of investigators has found that the eye disease is more prevalent than first thought.

The companies note that the partnership will propel Ray Therapeutics’ lead optogenetics gene therapy to Phase 1-2 clinical trials.

A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.

This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.

Government, academia and industry team up to streamline gene therapy development.

Polygenic risk score allows multiple variants to be tested simultaneously.

The POAAGG study in African Americans gives insights into the effect of glaucoma on this population and provides data that could lead to gene therapies.

Trial results indicate that retinal cell injections improve vision in certain retinitis pigmentosa patients.

Development of new animal model enhances study of genetic mutations.

During a presentation at the EURETINA 2021 Virtual Congress, Dr José-Alain Sahel explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.

Investigators have found that 1 intravitreal injection of an adeno-associated virus encoding an immunosuppressive transgene, either HLA-G or eqIL-10, reduced the clinical and histologic inflammation in a well-established model of autoimmune uveitis.

Gene therapy has produced early and lasting improvements in retinal cell morphology and visual acuity in a patient with inherited retinal disease.

RGX-314 viewed by investigators as a therapeutic option for exudative AMD.

Investigators are conducting retinal gene therapy trials that offer potential new treatments for inherited causes of vision loss.